KREBSDIAGNOSTIK MIT NICHTCODIERENDEN TRANSKRIPTEN
European patent · EP2791359 · In force
Register entry
- Publication number
- EP2791359
- Application number
- EP12857492
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Dec 13, 2012
- Published
- Oct 22, 2014
- Granted
- Jan 15, 2020
- Protection ends at the latest
- Dec 12, 2032
- Next annual fee due
- Dec 31, 2026
- IPC classes
- C12Q 1/68 (2018.01)C12M 1/34 (2006.01)G01N 33/574 (2006.01)C12N 15/11 (2006.01)
- Priority
- US 201161570194 P 13.12.2011US 201261652044 P 25.05.2012US 201261730426 P 27.11.2012
- PCT application
- PCT/US2012/069571 13.12.2012
- PCT publication
- WO2013/090620 20.06.2013
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Jan 1, 2026
Change
Published in Swissreg on 01.01.2026
- Jan 1, 2025
Change
Published in Swissreg on 01.01.2025
- Jan 1, 2024
Change
Published in Swissreg on 01.01.2024
- Oct 20, 2023
Transferred
- Owner
- Decipher Biosciences, Inc., 10355 Science Center Drive, Suite 240, San Diego, CA 92121, USA → Veracyte, Inc., Suite 300, 6000 Shoreline Ct, South San Francisco, CA 94080, USA
- Representative
- BOVARD AG, Patent- und Markenanwälte, Optingenstrasse 16, 3013 Bern
Published in Swissreg on 20.10.2023
- Jan 1, 2023
Change
Published in Swissreg on 01.01.2023
- Jan 15, 2020
Granted
Published in Swissreg on 15.01.2020
Parties
Inventor
VERGARA CORREA, Ismael, A.
West Vancouver, British Columbia V7W 1C3, CA
DAVICIONI, Elai
La Jolla, CA 92037, US
ERHO, Nicholas, George
Vancouver, Bristish Columbia V6H 1Y2, CA
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.